Neutrophil–lymphocyte ratio being associated with mortality risk in patients receiving antifibrotic therapy
- 7 February 2024
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 223, 107542
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science
This publication has 27 references indexed in Scilit:
- Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosiseClinicalMedicine, 2022
- Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trialThe Lancet Respiratory Medicine, 2021
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung DiseaseNew England Journal of Medicine, 2019
- Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort studyThe Lancet Respiratory Medicine, 2019
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Asthma phenotypes: the evolution from clinical to molecular approachesNature Medicine, 2012
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011